Related Experiment Video
Updated: Sep 20, 2025

Electrochemotherapy of Tumours
Published on: December 15, 2008
Electrochemotherapy and immune interactions; A boost to the system?
Maura B Bendix1, Aileen Houston2, Patrick F Forde3
1CancerResearch@UCC, University College Cork, Western Gateway Building, Western Road, Cork, Ireland; APC Microbiome Ireland, University College Cork, Cork, Ireland.
Abstract:
Electrochemotherapy (ECT), the application of an electric impulse to deliver chemotherapy drugs into cells, has been in clinical trials since the early 1990s and has been used for a variety of different malignancies including melanoma and sarcoma. A standard operating procedure for the use of ECT in clinical settings has been established since 2006. ECT is very effective in reducing the local tumour burden via T-cell dependent killing of the cancer cells; however abscopal effects are not consistently observed. Currently little is known or understood about how ECT affects the immune cell population within the treated tumour and how these changes could impact the immune response. In this manuscript, we will review the current knowledge on ECT in the context of its interactions with the immune system and discuss how the gained knowledge could be harnessed to develop a potent ECT-immune co-treatment combination (Electroimmunotherapy).
Related Concept Videos
Tumor Immunotherapy
Cell-mediated Immune Responses
Electroconvulsive Therapy
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
The Tumor Microenvironment
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

